Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Bullish +75

Cardinal Health's sell-off on earnings was an overreaction. We'd be buyers

📉 Cardinal Health's stock dropped 4.9% following its quarterly earnings report on Thursday.

✋ Analysts from the firm consider this decline an overreaction and state they would buy shares if allowed to trade.

⏱️ Jim Cramer mentioned Cardinal on CNBC TV, triggering a 72-hour trading restriction for his charitable trust which prevents an immediate purchase.

📈 The investment thesis is built on the company's track record of delivering double-digit earnings-per-share growth.

👵 A key positive driver is Cardinal's exposure to the secular trend of an aging U.S. population.

💊 The company has expanded into faster-growing, higher-margin areas such as specialty pharmaceutical distribution and management services organizations.

⚠️ Thursday's fiscal 2026 third-quarter report missed top-line expectations and included a $184 million goodwill impairment charge for its Navista and ION reporting units.

🗣️ CEO Jason Hollar confirmed that this impairment will not change their strategy regarding the MSO business line.

🎯 Management remains confident in growing adjusted earnings for fiscal 2027 within the long-term target range of 12% to 14%.

📊 Based on those estimates, Cardinal's shares are now trading at approximately 16.5 times next 12-month earnings, down from about 20x in early March.

🤝 Multiple Wall Street analysts, including Jefferies and Leerink Partners, have defended the stock and see no reason for the share price to be off without a massive rotation.

💧 Cardinal is described as a "good house in a bad neighborhood" within the healthcare sector, which currently has stocks that are out of favor.

🔄 When healthcare sentiment improves, analysts believe this well-positioned company will be among the first to be bought by investors.

Bullish Signals
  • Cardinal Health has a track record of delivering double-digit earnings-per-share growth, supported by the secular tailwind of an aging U.S. population.
  • The company has successfully expanded into faster-growing, higher-margin areas including specialty pharmaceutical distribution, at-home delivery, and management services organizations (MSOs).
  • CEO Jason Hollar reaffirmed confidence in growing adjusted earnings for fiscal 2027 within the long-term target range of 12% to 14%.
  • Valuation appears attractive as shares are trading at roughly 16.5 times the next 12 months' estimates, down from about 20x earnings when the stake was taken in early March.
  • Major Wall Street analysts support the positive outlook; Jefferies stated its thesis on Cardinal Health remains unchanged despite recent market overreaction.
  • Leerink Partners notes that momentum for Cardinal Health remains robust and that a pullback presents an opportunistic buying opportunity.
Risk Factors
  • Cardinal Health's stock price declined by 4.9% on Thursday following an earnings miss.
  • The company booked a $184 million goodwill impairment charge for its Navista and ION reporting units, creating market noise despite management's strategy remaining unchanged.
  • The article explicitly states that the top-line earnings report missed investor expectations.
  • Cardinal Health traded at roughly 16.5 times forward earnings in late September, a significant drop from the approximately 20 times multiple seen in early March when the author took a stake.
Full Analysis
Kevin Stankiewicz from the Investing Club argues that Cardinal Health's (CAH) significant sell-off on Thursday was an overreaction and expresses a strong desire to buy shares if not restricted by CNBC trading rules. The author notes that Jim Cramer mentioned the stock on CNBC TV on Thursday, which triggers a mandatory 72-hour wait for his charitable trust before executing trades, preventing an immediate purchase despite their bullish thesis. Cardinal Health's quarterly results showed a top-line miss and a surprise $184 million goodwill impairment charge related to its Navista and ION reporting units within the management services organizations (MSOs) business line, which Cramer wished had been better telegraphed by management. However, CEO Jason Hollar reassured investors that this accounting event will not alter the company's strategic direction for MSOs. The core investment thesis relies on Cardinal Health's history of delivering double-digit earnings-per-share growth and its positioning within secular tailwinds such as an aging U.S. population. The company has successfully expanded into higher-margin areas including specialty pharmaceutical distribution, at-home delivery, and non-distribution businesses like MSOs. Financial metrics support the buy view, as the stock is trading at approximately 16.5 times next 12 months' estimates per FactSet data, down from around 20 times earnings when the club established its stake in early March. This valuation compression provides a margin of safety while management remains confident in guiding adjusted earnings growth for fiscal 2027 within its long-term target range of 12% to 14%. Wall Street analysts largely agree with this sentiment, reinforcing that the pullback presents an opportunity rather than a risk. Jefferies stated its thesis on Cardinal remains unchanged, while Leerink Partners noted that momentum remains robust and investors' high expectations were not fully supported by the "print." The club views healthcare stocks generally as being out of favor in the current market, creating a situation where a quality company like Cardinal could be a leading candidate when sentiment improves. They describe Cardinal as "a good house in a bad neighborhood," suggesting it should be purchased first once the broader sector begins to recover from its recent underperformance and rotation moves.